Gynecological Cancer: Diagnosis and Management

Dear Colleagues,

The past decade was eventful in terms of diagnostic and therapeutic advances in the field of gynaecological cancer. In terms of surgical treatment, in cervical cancer, the rise and fall of minimally invasive surgery in early stages leaves the debate open, while in the cytoreductive surgery of ovarian cancer, the extended operations for complete tumour reduction became the standard of care, but patient selection for the latter operations is still an open issue. Targeted therapies have emerged in cervical, ovarian, and endometrial cancers in the past few years, becoming standards of care in international guidelines, with more and more information gained on the genetic background of these diseases. The deeper understanding of the molecular level of these tumours started a breakthrough in the diagnostic, prognostic, and therapeutic approaches. There is emerging data on the role of the microbiome in the pathogenesis of these tumours. In addition to prognostic factors, with the increasing number of cancer survivors, the questions of the quality of life, vaginal health, and sexual functions come into focus as well.

The topics of this Special Issue should focus on, but are not limited to, the following:

• New biomarkers of screening and early detection in gynaecological cancers;
• New biomarker-driven targeted treatment in gynaecological malignancies;
• Preoperative assessment of gynaecological cancers;
• Predictive value of biomarkers in the medical or surgical treatment of gynaecological cancers;
• Surgical treatment of gynaecological cancers;
• Immune environment and progress in immunotherapy of gynaecological cancers;
• The role of the microbiome in gynaecological cancers;
• Prognostic and therapeutic relevance of DNA repair defects;
• Investigating the determinants of health-related quality of life in patients with gynaecological cancer;
• Investigating and maintaining vaginal health and sexual functions in gynaecological cancer;
• Gynaecological cancer and thrombosis.

Submissions of original preclinical or clinical papers contributing to the advances in this field, as well as reviews, are encouraged.

Dr. Zoard T. Krasznai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• biomarkers
• ovarian cancer
• cervical cancer
• endometrial cancer
• immunotherapy
• targeted therapy
• survival analysis
• quality of life
• screening
• early detection
• treatment
• surgery
• microbiome